Vol. 13 No. 1 (2021): Archives of Public Health
Clinical Science

Influence of alendronate therapy on the results of densitometric examination after implantation of total hip endoprosthesis

Ilir Shabani
University Clinic for Traumatology, Orthopedics, Anesthesiology, Reanimation and Intensive Care; Ss Cyril and Methodius in Skopje, Faculty of Medicine, Republic of North Macedonia
Antonio Gavrilovski
University Clinic for Traumatology, Orthopedics, Anesthesiology, Reanimation and Intensive Care; Ss Cyril and Methodius in Skopje, Faculty of Medicine, Republic of North Macedonia
Vilijam Velkovski
University Clinic for Traumatology, Orthopedics, Anesthesiology, Reanimation and Intensive Care; Ss Cyril and Methodius in Skopje, Faculty of Medicine, Republic of North Macedonia
Nenad Atanasov
University Clinic for Traumatology, Orthopedics, Anesthesiology, Reanimation and Intensive Care; Ss Cyril and Methodius in Skopje, Faculty of Medicine, Republic of North Macedonia
Shaban Memeti
University Clinic for Chidren's Surgery; Ss Cyril and Methodius in Skopje, Faculty of Medicine, Republic of North Macedonia
Anila Belchishta
University Clinic for Traumatology, Orthopedics, Anesthesiology, Reanimation and Intensive Care; Ss Cyril and Methodius in Skopje, Faculty of Medicine, Republic of North Macedonia

Published 2021-06-20

Keywords

  • total hip endoprosthesis,
  • alendronate therapy,
  • DXA

How to Cite

1.
Shabani I, Gavrilovski A, Velkovski V, Atanasov N, Memeti S, Belchishta A. Influence of alendronate therapy on the results of densitometric examination after implantation of total hip endoprosthesis. Arch Pub Health [Internet]. 2021 Jun. 20 [cited 2021 Dec. 7];13(1):32-8. Available from: https://id-press.eu/aph/article/view/5994

Abstract

The development of aloarthroplasty of the hip is continuously rising. After implantation of a total cement-free hip endoprosthesis, often there is a periprosthetic femoral bone loss. Alendronate has been shown to be a potent inhibitor of bone resorption activity; it inhibits osteoclastic bone resorption, increases bone mass, and plays a significant role in post-implantation stabilization of the femur. The aim of this study was to determine the effect of alendronate on osteointegration of hip endoprosthesis.Material and methods: The study analyzed 10 patients operated on with implantation of a total cement-free hip endoprosthesis (THP). The included patients were examined by a radiographic method at 6 and 12 months and DXA method at 6 and 12 months. Results: The study showed differences in the values of bone mineral density and bone mineral content in the interval between 6 and 12 months in patients undergoing THP, and hence we can conclude that alendronate therapy after THP implantation reduced periprosthetic loss of bone mass and implant stiffening. Alendronate is a proven inhibitor of periprosthetic bone loss that occurs after prirmary impantation of a total cement-free hip endoprosthesis.

Downloads

Download data is not yet available.

References

  1. Kobayashi S, Saito N, Horiuchi H, Iorio R, Takaoka K. Poor bone quality or hip structure as a risk factors affecting survival of total hip arthroplasty. Lancet 2000;355:1499-1504.
  2. Taylor M, Tanner KE. Fatigue failure of cancellous bone: a possible cause of implant migration and loosening. J Bone Joint Surg Br 1997;779:181-182. DOI: https://doi.org/10.1302/0301-620X.79B2.0790181
  3. Bobyn JD, Mortimer ES, Glassman AH, et al. Producing and avoiding stress shielding. Laboratory and Clinical observation of noncemented total hip arthroplasty. Clin Orthop Relat Res 1992;274:79-96.
  4. Huiskes R. The various stress patterns of press-fit, ingrown, and cemented femoral stems. Clin Orthop Relat Res 1990;(261):27-38. DOI: https://doi.org/10.1097/00003086-199012000-00006
  5. Sychterz CJ, Engha CA. The influence of clinical factors on periprosthetic bone remodeling Clin Orthop Relat Res 1995;322:285-292. DOI: https://doi.org/10.1097/00003086-199601000-00034
  6. Kiratli BJ, Checovich MM. Mc Beath AA, Wilson MA, Heiner JP. Measurment of bone mineral density by DEXA in patiens with a Wisconsin hip, an uncemented femoral stem. J Arthroplasty 1996;1(2):184-193
  7. Hosking D, Chilvers CE, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338(8):485–492) 1(2):184-193 DOI: https://doi.org/10.1056/NEJM199802193380801
  8. McCarthy CK, Steinberg GG, Agren M, Leahey D, Wyman E, Baran DT. Quantifying bone loss from the proximal femur after total hip arthroplasty. J Bone Joint Surg Br 1991; 73(5):774-778. DOI: https://doi.org/10.1302/0301-620X.73B5.1894664
  9. Kiratli BJ, Checovich MM, McBeath AA, Wilson MA, Heiner JP. Measurement of bone mineral density by dual-energy x-ray absorptiometry in patients with the Wisconsin hip, an uncemented femoral stem. J Arthroplasty 1996; 11(2):184-193. DOI: https://doi.org/10.1016/S0883-5403(05)80015-4
  10. Kröger H, Venesmaa P, Jurvelin J, Miettinen H, Suomalainen O, Alhava E. Bone density at the proximal femur after total hop arthroplasty. Clin Orthop Relat Res 1998; (352):66-74. DOI: https://doi.org/10.1097/00003086-199807000-00009
  11. Brodner W, Bitzan P, Lomoschitz F, et al. Changes in bone mineral density in the proximal femur after cementless total hip arthroplasty. A five-year longitudinal study. J Bone Joint Surg Br 2004; 86(1):20-26. DOI: https://doi.org/10.1302/0301-620X.86B1.14637
  12. Braun A, Papp J, Reiter A. The periprosthetic bone remodeling process—signs of vital bone reaction. Int Orthop 2003; 27(Suppl 1):S7-10.
  13. Kobayashi S, Saito N, Horiuchi H, Iorio R, Takaoka K. Poor bone quality or hip structure as risk factors affecting survival of total-hip arthroplasty. Lancet 2000; 355(9214):1499-1504. DOI: https://doi.org/10.1016/S0140-6736(00)02164-4
  14. Woolf AD, Akesson K. Preventing fractures in elderly people. BMJ 2003; 327(7406):89-95. DOI: https://doi.org/10.1136/bmj.327.7406.89
  15. Shanbhag AS. Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg 2006; 14(4):215-225. DOI: https://doi.org/10.5435/00124635-200604000-00003
  16. Charnley J.Low Friction Arthroplasty of the hip theory and practice. New York ,NY:Spingr Verlog;1979 DOI: https://doi.org/10.1007/978-3-642-67013-8
  17. Older J.Charnley low-friction arthroplasty: a worldwide retrospective review at 15 to 20 yars. J Arthroplasty 2002;17:675-680 DOI: https://doi.org/10.1054/arth.2002.31973
  18. Wroblewski BM, Charnley J. Radiographic morphology of the osteoarthritis hip. J Bone Joint Surg Br1982;64:568-569. DOI: https://doi.org/10.1302/0301-620X.64B5.7142263
  19. Tapaninen TS, Venesmaa PK, Jurvelin JS, Miettinen HJ, Kröger HP. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty—a 5-year follow-up of 16 patients. Scand J Surg 2010; 99(1):32-37. DOI: https://doi.org/10.1177/145749691009900108
  20. Arabmotlagh M, Rittmeister M, Hennigs T. Alendronate prevents femoral periprosthetic bone losss following total hip arthroplasty: prospective randomized double-blind study. J Orthop Res 2004; 24(7):1336-1341. DOI: https://doi.org/10.1002/jor.20162
  21. Venesmaa PK, Kröger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res 2001; 16(11):2126-21.
  22. Petri K.Venesmaa, Heikki P.J.Kroger, Hannu J. A.Miettinen et al. Alendronate reduces periprosthetic Bone Loss after uncemented primary Hip arthroplasty. Journal of bone and mineral research 2001;16(11)2126-2131 DOI: https://doi.org/10.1359/jbmr.2001.16.11.2126
  23. Nehme A, Maalouf G, Tricoire JL, Giordano G, Chiron P, Puget J. Effect of alendronate on periprosthetic bone loss after uncemented primary total hip arthroplasty :a prospective randomized study. Rev Chir Orthoped Reparatrice Appar Mot.2003.
  24. Nishioka T, Yagi S, Mitsuhashi T, et al. Alendronate inhibits periprosthetic bone loss around uncemented femoral components. J Bone Miner Metab 2007; 25(3):179-183. DOI: https://doi.org/10.1007/s00774-006-0743-7
  25. Wilkinson JM, Stockley I, Peel NF, et al. Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res 2001; 16(3):556-564. DOI: https://doi.org/10.1359/jbmr.2001.16.3.556
  26. Bobyn JD, Mortimer ES, Glassman AH, Engh CA, Miller JE, Brooks CE. Producing and avoiding stress shielding. Laboratory and clinical observations of noncemented total hip. Clin Orthop Relat Res 1992; (274):79-96. DOI: https://doi.org/10.1097/00003086-199201000-00010
  27. Nakamura K. Measurement of periprosthetic bone mineral density after cementless hip arthroplasty by dual energy X-ray absorptiometry:Longitudinal and cross-sectional evaluation. J Orthop Sci 1996; 1:113-122. DOI: https://doi.org/10.1007/BF02348802
  28. Venesmaa PK, Kroger HPJ, Miettinen HJA, Jurvelin JS, Suomalainen OT, Alhava EM. Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy X-ray absorptiometry a 3 –year follow-up study.J Bone Miner Res200;1 16:1056-1061. DOI: https://doi.org/10.1359/jbmr.2001.16.6.1056
  29. Engh CA, McGovern TF, Bobyn JD, Harris WH. A quantitative evaluation of periprosthetic bone –remodeling after cementless total hip arthroplasty. J Bone Joint Surg Am 1992;74:1009-1020. DOI: https://doi.org/10.2106/00004623-199274070-00007